We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+1.77%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$2.42B
AUM Growth
+$89M
Cap. Flow
+$262M
Cap. Flow %
10.81%
Top 10 Hldgs %
65.82%
Holding
53
New
8
Increased
8
Reduced
9
Closed
2

Top Buys

Rank Stock Value
1
EWTX icon
Edgewise Therapeutics
EWTX
+$181M
2
BOLT icon
Bolt Biotherapeutics
BOLT
+$147M
3
BABA icon
Alibaba
BABA
+$52.8M
4
LVTX
LAVA Therapeutics
LVTX
+$45.7M
5
LEGN icon
Legend Biotech
LEGN
+$6.93M

Top Sells

Rank Stock Value
1
CTLT
CATALENT, INC.
CTLT
+$104M
2
INGN icon
Inogen
INGN
+$39.4M
3
VRNA
Verona Pharma
VRNA
+$14.7M
4
INZY
Inozyme Pharma
INZY
+$13.2M
5
HRMY icon
Harmony Biosciences
HRMY
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 65.06%
2 Financials 5.64%
3 Technology 5.23%
4 Communication Services 3.57%
5 Consumer Discretionary 2.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Morningstar Total Stock Market ETF
VTI
$657B
$400M 16.51%
1,933,900
– –
EWTX icon
2
Edgewise Therapeutics
EWTX
$4.42B
$182M 7.5%
+5,587,207
New +$181M
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$167M 6.91%
2,645,446
– –
BOLT icon
4
Bolt Biotherapeutics
BOLT
$7.47M
$148M 6.12%
+225,200
New +$147M
INGN icon
5
Inogen
INGN
$174M
$145M 5.98%
2,759,320
-790,000
-22% -$39.4M
BN icon
6
Brookfield
BN
$103B
$137M 5.64%
5,738,048
– –
AAPL icon
7
Apple
AAPL
$4.9T
$127M 5.23%
1,037,404
– –
HRMY icon
8
Harmony Biosciences
HRMY
$2.08B
$110M 4.55%
3,336,378
-286,093
-8% -$10M
NKTX icon
9
Nkarta
NKTX
$154M
$91.9M 3.8%
2,793,864
– –
CABO icon
10
Cable One
CABO
$224M
$86.6M 3.57%
47,341
-5,000
-10% -$9.77M
SPRB
11
Spruce Biosciences
SPRB
$119M
$82.8M 3.42%
66,524
– –
PRAX icon
12
Praxis Precision Medicines
PRAX
$8.58B
$80M 3.3%
162,805
– –
ALGS icon
13
Aligos Therapeutics
ALGS
$26.7M
$59.5M 2.46%
104,583
– –
LVTX
14
DELISTED
LAVA Therapeutics
LVTX
$50.5M 2.09%
+3,327,312
New +$45.7M
BABA icon
15
Alibaba
BABA
$279B
$48.7M 2.01%
+214,827
New +$52.8M
MIRM icon
16
Mirum Pharmaceuticals
MIRM
$6.87B
$48.5M 2%
2,445,147
– –
INZY
17
DELISTED
Inozyme Pharma
INZY
$39M 1.61%
1,969,379
-600,000
-23% -$13.2M
EAR
18
DELISTED
Eargo, Inc. Common Stock
EAR
$36.8M 1.52%
36,854
– –
FRLN
19
DELISTED
Freeline Therapeutics Holdings plc American Depositary Shares
FRLN
$29M 1.2%
157,415
– –
CMPI
20
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$26.3M 1.09%
2,170,100
– –
SPNE
21
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
$23M 0.95%
1,321,006
-18,079
-1% -$324K
PTGX icon
22
Protagonist Therapeutics
PTGX
$8.92B
$22.5M 0.93%
867,724
– –
GRTX
23
DELISTED
Galera Therapeutics, Inc. Common Stock
GRTX
$21.7M 0.9%
2,459,021
-500,000
-17% -$5.49M
FOLD
24
DELISTED
Amicus Therapeutics
FOLD
$19.4M 0.8%
1,962,880
+278,085
+17% +$4.3M
BPMC
25
DELISTED
Blueprint Medicines
BPMC
$19.2M 0.79%
197,000
– –
1
2 3

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return

Novo Holdings A/S's Q1 2021 Portfolio in Review

As of Q1 2021, Novo Holdings A/S held 53 positions worth $2.42B, up 3.8% from $2.33B the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Novo Holdings A/S deployed $262M of net new capital in Q1 2021, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Edgewise Therapeutics: 5,587,207 shares worth $182M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, down from 66% a quarter earlier, followed by Financials and Technology.

On the sell side, the largest reduction was Inogen, an estimated $39.4M trimmed.

  • Novo Holdings A/S's largest Q1 2021 buy was Edgewise Therapeutics: 5,587,207 shares worth $182M.
  • Novo Holdings A/S added most to Amicus Therapeutics in Q1 2021, an estimated $4.3M increase.
  • Novo Holdings A/S's biggest Q1 2021 reduction was Inogen, cutting an estimated $39.4M.
  • Novo Holdings A/S fully exited CATALENT, INC. in Q1 2021, selling an estimated $104M.
  • Novo Holdings A/S's ten largest holdings make up 66% of its $2.42B portfolio in Q1 2021.
  • Novo Holdings A/S opened 8 new positions and closed 2 in Q1 2021.
  • Novo Holdings A/S's portfolio value rose 3.8% quarter-over-quarter to $2.42B.

Based on Novo Holdings A/S's 13F filing for Q1 2021, filed 17 May 2021.